{"id":"W4200502653","doi":"10.1097/qad.0000000000003025","title":"Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","year":2021,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Rilpivirine; Tolerability; Regimen; Medicine; Internal medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load; Phases of clinical research; Adverse effect; Clinical trial; Virology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004073669,0.0002524689,0.0005563395,0.0001086562,0.0001232255,0.00001544691,0.00004072528,0.00004330198,0.00004414143],"category_scores_gemma":[0.0002716798,0.0001699939,0.0001121692,0.0003183641,0.00003042711,0.00006406727,0.00003259208,0.00007213139,0.00001546665],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001758448,"about_ca_system_score_gemma":0.0003461302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000638267,"about_ca_topic_score_gemma":0.00006220486,"domain_scores_codex":[0.9982939,0.00008370868,0.000473661,0.0004858658,0.0003832627,0.0002795451],"domain_scores_gemma":[0.9986413,0.0002583886,0.0001784461,0.0004365434,0.0003652167,0.0001201739],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.01850518,0.03568792,0.2744079,0.000296012,0.004002091,0.003156509,0.01822003,0.00008997996,0.03392619,0.00004101669,0.001105092,0.6105621],"study_design_scores_gemma":[0.3817657,0.1246464,0.0692547,0.002208244,0.008765377,0.0005219596,0.03078485,0.004878327,0.3660966,0.00007295384,0.009673723,0.001331185],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959415,0.0002111997,0.0006575873,0.0008096822,0.00006601458,0.001427079,0.000047108,0.00004850007,0.0007912935],"genre_scores_gemma":[0.9572318,0.0000197395,0.02345299,0.00003045547,0.00008428245,0.0001750215,0.0003644335,0.00003651787,0.01860477],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6092309,"threshold_uncertainty_score":0.6932151,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07318126596459043,"score_gpt":0.3788883562795782,"score_spread":0.3057070903149878,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}